Electron paramagnetic resonance

From Wikipedia, the free encyclopedia

https://en.wikipedia.org/wiki/Electron_paramagnetic_resonance

Electron paramagnetic resonance (EPR) or electron spin resonance (ESR) spectroscopy is a method for studying materials that have unpaired electrons. The basic concepts of EPR are analogous to those of nuclear magnetic resonance (NMR), but the spins excited are those of the electrons instead of the atomic nuclei. EPR spectroscopy is particularly useful for studying metal complexes and organic radicals. EPR was first observed in Kazan State University by Soviet physicist Yevgeny Zavoisky in 1944, and was developed independently at the same time by Brebis Bleaney at the University of Oxford.

Typical set-up for recording EPR spectra. The user would be seated next to the RF generator, magnet, and controls for sample temperature.

Theory

Origin of an EPR signal

Every electron has a magnetic moment and spin quantum number ${\displaystyle s=\frac{1}{2}}$, with magnetic components ${\displaystyle m_{\mathrm{s}}=+\frac{1}{2}}$ or ${\displaystyle m_{\mathrm{s}}=-\frac{1}{2}}$. In the presence of an external magnetic field with strength ${\displaystyle B_0}$, the electron's magnetic moment aligns itself either antiparallel (${\displaystyle m_{\mathrm{s}}=-\frac{1}{2}}$) or parallel (${\displaystyle m_{\mathrm{s}}=+\frac{1}{2}}$) to the field, each alignment having a specific energy due to the Zeeman effect:

${\displaystyle E=m_s{g}_e{\mu }_{\text{B}}{B}_0,}$

where

• ${\displaystyle g_e}$ is the electron's so-called g-factor (see also the Landé g-factor), ${\displaystyle g_{\mathrm{e}}=2.0023}$ for the free electron,
• ${\displaystyle {\mu }_{\text{B}}}$ is the Bohr magneton.

Therefore, the separation between the lower and the upper state is ${\displaystyle \mathrm{\Delta }E=g_e{\mu }_{\text{B}}{B}_0}$ for unpaired free electrons. This equation implies (since both ${\displaystyle g_e}$and ${\displaystyle {\mu }_{\text{B}}}$ are constant) that the splitting of the energy levels is directly proportional to the magnetic field's strength, as shown in the diagram below.

An unpaired electron can change its electron spin by either absorbing or emitting a photon of energy ${\displaystyle h\nu }$ such that the resonance condition, ${\displaystyle h\nu =\mathrm{\Delta }E}$, is obeyed. This leads to the fundamental equation of EPR spectroscopy: ${\displaystyle h\nu =g_e{\mu }_{\text{B}}{B}_0}$.

Experimentally, this equation permits a large combination of frequency and magnetic field values, but the great majority of EPR measurements are made with microwaves in the 9000–10000 MHz (9–10 GHz) region, with fields corresponding to about 3500 G (0.35 T). Furthermore, EPR spectra can be generated by either varying the photon frequency incident on a sample while holding the magnetic field constant or doing the reverse. In practice, it is usually the frequency that is kept fixed. A collection of paramagnetic centers, such as free radicals, is exposed to microwaves at a fixed frequency. By increasing an external magnetic field, the gap between the ${\displaystyle m_{\mathrm{s}}=+\frac{1}{2}}$ and ${\displaystyle m_{\mathrm{s}}=-\frac{1}{2}}$ energy states is widened until it matches the energy of the microwaves, as represented by the double arrow in the diagram above. At this point the unpaired electrons can move between their two spin states. Since there typically are more electrons in the lower state, due to the Maxwell–Boltzmann distribution (see below), there is a net absorption of energy, and it is this absorption that is monitored and converted into a spectrum. The upper spectrum below is the simulated absorption for a system of free electrons in a varying magnetic field. The lower spectrum is the first derivative of the absorption spectrum. The latter is the most common way to record and publish continuous wave EPR spectra.

For the microwave frequency of 9388.4 MHz, the predicted resonance occurs at a magnetic field of about ${\displaystyle B_0=h\nu /g_e{\mu }_{\text{B}}}$ = 0.3350 T = 3350 G

Because of electron-nuclear mass differences, the magnetic moment of an electron is substantially larger than the corresponding quantity for any nucleus, so that a much higher electromagnetic frequency is needed to bring about a spin resonance with an electron than with a nucleus, at identical magnetic field strengths. For example, for the field of 3350 G shown above, spin resonance occurs near 9388.2 MHz for an electron compared to only about 14.3 MHz for ¹H nuclei. (For NMR spectroscopy, the corresponding resonance equation is ${\displaystyle h\nu =g_{\mathrm{N}}{\mu }_{\mathrm{N}}{B}_0}$ where ${\displaystyle g_{\mathrm{N}}}$ and ${\displaystyle {\mu }_{\mathrm{N}}}$ depend on the nucleus under study.)

Field modulation

The field oscillates between B₁ and B₂ due to the superimposed modulation field at 100 kHz. This causes the absorption intensity to oscillate between I₁ and I₂. The larger the difference the larger the intensity detected by the detector tuned to 100 kHz (note this can be negative or even 0). As the difference between the two intensities is detected the first derivative of the absorption is detected.

As previously mentioned an EPR spectrum is usually directly measured as the first derivative of the absorption. This is accomplished by using field modulation. A small additional oscillating magnetic field is applied to the external magnetic field at a typical frequency of 100 kHz. By detecting the peak to peak amplitude the first derivative of the absorption is measured. By using phase sensitive detection only signals with the same modulation (100 kHz) are detected. This results in higher signal to noise ratios. Note field modulation is unique to continuous wave EPR measurements and spectra resulting from pulsed experiments are presented as absorption profiles.

The same idea underlies the Pound-Drever-Hall technique for frequency locking of lasers to a high-finesse optical cavity.

Maxwell–Boltzmann distribution

In practice, EPR samples consist of collections of many paramagnetic species, and not single isolated paramagnetic centers. If the population of radicals is in thermodynamic equilibrium, its statistical distribution is described by the Boltzmann distribution:

${\displaystyle \frac{n_{\text{upper}}}{n_{\text{lower}}}=\exp \left(-\frac{E_{\text{upper}}-E_{\text{lower}}}{kT}\right)=\exp \left(-\frac{\mathrm{\Delta }E}{kT}\right)=\exp \left(-\frac{ϵ}{kT}\right)=\exp \left(-\frac{h\nu }{kT}\right)}$

where ${\displaystyle n_{\text{upper}}}$ is the number of paramagnetic centers occupying the upper energy state, ${\displaystyle k}$ is the Boltzmann constant, and ${\displaystyle T}$ is the thermodynamic temperature. At 298 K, X-band microwave frequencies (${\displaystyle \nu }$ ≈ 9.75 GHz) give ${\displaystyle n_{\text{upper}}/n_{\text{lower}}}$ ≈ 0.998, meaning that the upper energy level has a slightly smaller population than the lower one. Therefore, transitions from the lower to the higher level are more probable than the reverse, which is why there is a net absorption of energy.

The sensitivity of the EPR method (i.e., the minimal number of detectable spins ${\displaystyle N_{\text{min}}}$) depends on the photon frequency ${\displaystyle \nu }$ according to

${\displaystyle N_{\text{min}}=\frac{k_{1}V}{Q_0{k}_f{\nu }^2{P}^{1/2}},\text{(Eq. 2)}}$

where ${\displaystyle k_1}$ is a constant, ${\displaystyle V}$ is the sample's volume, ${\displaystyle Q_0}$ is the unloaded quality factor of the microwave cavity (sample chamber), ${\displaystyle k_f}$ is the cavity filling coefficient, and ${\displaystyle P}$ is the microwave power in the spectrometer cavity. With ${\displaystyle k_f}$ and ${\displaystyle P}$ being constants, ${\displaystyle N_{\text{min}}}$ ~ ${\displaystyle (Q_0{\nu }^2{)}^{-1}}$, i.e., ${\displaystyle N_{\text{min}}}$ ~ ${\displaystyle {\nu }^{-\alpha }}$, where ${\displaystyle \alpha }$ ≈ 1.5. In practice, ${\displaystyle \alpha }$ can change varying from 0.5 to 4.5 depending on spectrometer characteristics, resonance conditions, and sample size.

A great sensitivity is therefore obtained with a low detection limit ${\displaystyle N_{\text{min}}}$ and a large number of spins. Therefore, the required parameters are:

• A high spectrometer frequency to minimize the Eq. 2. Common frequencies are discussed below
• A low temperature to decrease the number of spin at the high level of energy as shown in Eq. 1. This condition explains why spectra are often recorded on sample at the boiling point of liquid nitrogen or liquid helium.

Spectral parameters

In real systems, electrons are normally not solitary, but are associated with one or more atoms. There are several important consequences of this:

1. An unpaired electron can gain or lose angular momentum, which can change the value of its g-factor, causing it to differ from ${\displaystyle g_e}$. This is especially significant for chemical systems with transition-metal ions.
2. Systems with multiple unpaired electrons experience electron–electron interactions that give rise to "fine" structure. This is realized as zero field splitting and exchange coupling, and can be large in magnitude.
3. The magnetic moment of a nucleus with a non-zero nuclear spin will affect any unpaired electrons associated with that atom. This leads to the phenomenon of hyperfine coupling, analogous to J-coupling in NMR, splitting the EPR resonance signal into doublets, triplets and so forth. Additional smaller splittings from nearby nuclei is sometimes termed "superhyperfine" coupling.
4. Interactions of an unpaired electron with its environment influence the shape of an EPR spectral line. Line shapes can yield information about, for example, rates of chemical reactions.
5. These effects (g-factor, hyperfine coupling, zero field splitting, exchange coupling) in an atom or molecule may not be the same for all orientations of an unpaired electron in an external magnetic field. This anisotropy depends upon the electronic structure of the atom or molecule (e.g., free radical) in question, and so can provide information about the atomic or molecular orbital containing the unpaired electron.

The g factor

Knowledge of the g-factor can give information about a paramagnetic center's electronic structure. An unpaired electron responds not only to a spectrometer's applied magnetic field ${\displaystyle B_0}$ but also to any local magnetic fields of atoms or molecules. The effective field ${\displaystyle B_{\text{eff}}}$ experienced by an electron is thus written

${\displaystyle B_{\text{eff}}=B_0(1-\sigma ),}$

where ${\displaystyle \sigma }$ includes the effects of local fields (${\displaystyle \sigma }$ can be positive or negative). Therefore, the ${\displaystyle h\nu =g_e{\mu }_{\text{B}}{B}_{\text{eff}}}$ resonance condition (above) is rewritten as follows:

${\displaystyle h\nu =g_e{\mu }_B{B}_{\text{eff}}=g_e{\mu }_{\text{B}}{B}_0(1-\sigma ).}$

The quantity ${\displaystyle g_e(1-\sigma )}$ is denoted ${\displaystyle g}$ and called simply the g-factor, so that the final resonance equation becomes

${\displaystyle h\nu =g{\mu }_{\text{B}}{B}_0.}$

This last equation is used to determine ${\displaystyle g}$ in an EPR experiment by measuring the field and the frequency at which resonance occurs. If ${\displaystyle g}$ does not equal ${\displaystyle g_e}$, the implication is that the ratio of the unpaired electron's spin magnetic moment to its angular momentum differs from the free-electron value. Since an electron's spin magnetic moment is constant (approximately the Bohr magneton), then the electron must have gained or lost angular momentum through spin–orbit coupling. Because the mechanisms of spin–orbit coupling are well understood, the magnitude of the change gives information about the nature of the atomic or molecular orbital containing the unpaired electron.

The shape of a powder-pattern EPR spectrum changes according to the distribution of the ${\displaystyle g}$ matrix principal values

In general, the g factor is not a number but a 3×3 matrix. The principal axes of this tensor are determined by the local fields, for example, by the local atomic arrangement around the unpaired spin in a solid or in a molecule. Choosing an appropriate coordinate system (say, x,y,z) allows one to "diagonalize" this tensor, thereby reducing the maximal number of its components from 9 to 3: g_xx, g_yy and g_zz. For a single spin experiencing only Zeeman interaction with an external magnetic field, the position of the EPR resonance is given by the expression g_xxB_x + g_yyB_y + g_zzB_z. Here B_x, B_y and B_z are the components of the magnetic field vector in the coordinate system (x,y,z); their magnitudes change as the field is rotated, so does the frequency of the resonance. For a large ensemble of randomly oriented spins (as in a fluid solution), the EPR spectrum consists of three peaks of characteristic shape at frequencies g_xxB₀, g_yyB₀ and g_zzB₀.

In first-derivative spectrum, the low-frequency peak is positive, the high-frequency peak is negative, and the central peak is bipolar. Such situations are commonly observed in powders, and the spectra are therefore called "powder-pattern spectra". In crystals, the number of EPR lines is determined by the number of crystallographically equivalent orientations of the EPR spin (called "EPR center").

At higher temperatures, the three peaks coalesce to a singlet, corresponding to g_iso, for isotropic. The relationship between g_iso and the components is:

${\displaystyle (g_{\mathrm{i}\mathrm{s}\mathrm{o}}{)}^2=(g_{xx}{)}^2+(g_{yy}{)}^2+(g_{zz}{)}^2}$

One elementary step in analyzing an EPR spectrum is to compare g_iso with the g-factor for the free electron, g_e. Metal-based radicals g_iso is typically well above g_e whereas organic radicals, g_iso ~ g_e.

The determination of the absolute value of the g factor is challenging due to the lack of a precise estimate of the local magnetic field at the sample location. Therefore, typically so-called g factor standards are measured together with the sample of interest. In the common spectrum, the spectral line of the g factor standard is then used as a reference point to determine the g factor of the sample. For the initial calibration of g factor standards, Herb et al. introduced a precise procedure by using double resonance techniques based on the Overhauser shift.

Hyperfine coupling

Since the source of an EPR spectrum is a change in an electron's spin state, the EPR spectrum for a radical (S = 1/2 system) would consist of one line. Greater complexity arises because the spin couples with nearby nuclear spins. The magnitude of the coupling is proportional to the magnetic moment of the coupled nuclei and depends on the mechanism of the coupling. Coupling is mediated by two processes, dipolar (through space) and isotropic (through bond).

This coupling introduces additional energy states and, in turn, multi-lined spectra. In such cases, the spacing between the EPR spectral lines indicates the degree of interaction between the unpaired electron and the perturbing nuclei. The hyperfine coupling constant of a nucleus is directly related to the spectral line spacing and, in the simplest cases, is essentially the spacing itself.

Two common mechanisms by which electrons and nuclei interact are the Fermi contact interaction and by dipolar interaction. The former applies largely to the case of isotropic interactions (independent of sample orientation in a magnetic field) and the latter to the case of anisotropic interactions (spectra dependent on sample orientation in a magnetic field). Spin polarization is a third mechanism for interactions between an unpaired electron and a nuclear spin, being especially important for ${\displaystyle \pi }$-electron organic radicals, such as the benzene radical anion. The symbols "a" or "A" are used for isotropic hyperfine coupling constants, while "B" is usually employed for anisotropic hyperfine coupling constants.

In many cases, the isotropic hyperfine splitting pattern for a radical freely tumbling in a solution (isotropic system) can be predicted.

Multiplicity

Simulated EPR spectra of the methyl and methoxymethyl radicals

• For a radical having M equivalent nuclei, each with a spin of I, the number of EPR lines expected is 2MI + 1. As an example, the methyl radical, CH₃, has three ¹H nuclei, each with I = 1/2, and so the number of lines expected is 2MI + 1 = 2(3)(1/2) + 1 = 4, which is as observed.
• For a radical having M₁ equivalent nuclei, each with a spin of I₁, and a group of M₂ equivalent nuclei, each with a spin of I₂, the number of lines expected is (2M₁I₁ + 1) (2M₂I₂ + 1). As an example, the methoxymethyl radical, H
  ₂C(OCH
  ₃) has two equivalent ¹H nuclei, each with I = 1/2 and three equivalent ¹H nuclei each with I = 1/2, and so the number of lines expected is (2M₁I₁ + 1) (2M₂I₂ + 1) = [2(2)(1/2) + 1] [2(3)(1/2) + 1] = 3×4 = 12, again as observed.
• The above can be extended to predict the number of lines for any number of nuclei.

While it is easy to predict the number of lines, the reverse problem, unraveling a complex multi-line EPR spectrum and assigning the various spacings to specific nuclei, is more difficult.

In the often encountered case of I = 1/2 nuclei (e.g., ¹H, ¹⁹F, ³¹P), the line intensities produced by a population of radicals, each possessing M equivalent nuclei, will follow Pascal's triangle. For example, the spectrum at the right shows that the three ¹H nuclei of the CH₃ radical give rise to 2MI + 1 = 2(3)(1/2) + 1 = 4 lines with a 1:3:3:1 ratio. The line spacing gives a hyperfine coupling constant of a_H = 23 G for each of the three ¹H nuclei. Note again that the lines in this spectrum are first derivatives of absorptions.

As a second example, the methoxymethyl radical, H₃COCH₂^. the OCH₂ center will give an overall 1:2:1 EPR pattern, each component of which is further split by the three methoxy hydrogens into a 1:3:3:1 pattern to give a total of 3×4 = 12 lines, a triplet of quartets. A simulation of the observed EPR spectrum is shown and agrees with the 12-line prediction and the expected line intensities. Note that the smaller coupling constant (smaller line spacing) is due to the three methoxy hydrogens, while the larger coupling constant (line spacing) is from the two hydrogens bonded directly to the carbon atom bearing the unpaired electron. It is often the case that coupling constants decrease in size with distance from a radical's unpaired electron, but there are some notable exceptions, such as the ethyl radical (CH₂CH₃).

Resonance linewidth definition

Resonance linewidths are defined in terms of the magnetic induction B and its corresponding units, and are measured along the x axis of an EPR spectrum, from a line's center to a chosen reference point of the line. These defined widths are called halfwidths and possess some advantages: for asymmetric lines, values of left and right halfwidth can be given. The halfwidth ${\displaystyle \mathrm{\Delta }{B}_h}$ is the distance measured from the line's center to the point in which absorption value has half of maximal absorption value in the center of resonance line. First inclination width ${\displaystyle \mathrm{\Delta }{B}_{1/2}}$ is a distance from center of the line to the point of maximal absorption curve inclination. In practice, a full definition of linewidth is used. For symmetric lines, halfwidth ${\displaystyle \mathrm{\Delta }{B}_{1/2}=2\mathrm{\Delta }{B}_h}$, and full inclination width ${\displaystyle \mathrm{\Delta }{B}_{\text{max}}=2\mathrm{\Delta }{B}_{1s}}$.

Applications

This low-temperature ESR-STM in the Center for Quantum Nanoscience is one of the first STMs globally to measure electron spin resonance on single atoms.

EPR/ESR spectroscopy is used in various branches of science, such as biology, chemistry and physics, for the detection and identification of free radicals in the solid, liquid, or gaseous state, and in paramagnetic centers such as F-centers.

Chemical reactions

EPR is a sensitive, specific method for studying both radicals formed in chemical reactions and the reactions themselves. For example, when ice (solid H₂O) is decomposed by exposure to high-energy radiation, radicals such as H, OH, and HO₂ are produced. Such radicals can be identified and studied by EPR. Organic and inorganic radicals can be detected in electrochemical systems and in materials exposed to UV light. In many cases, the reactions to make the radicals and the subsequent reactions of the radicals are of interest, while in other cases EPR is used to provide information on a radical's geometry and the orbital of the unpaired electron.

EPR is useful in homogeneous catalysis research for characterization of paramagnetic complexes and reactive intermediates. EPR spectroscopy is a particularly useful tool to investigate their electronic structures, which is fundamental to understand their reactivity.

EPR/ESR spectroscopy can be applied only to systems in which the balance between radical decay and radical formation keeps the free radicals concentration above the detection limit of the spectrometer used. This can be a particularly severe problem in studying reactions in liquids. An alternative approach is to slow down reactions by studying samples held at cryogenic temperatures, such as 77 K (liquid nitrogen) or 4.2 K (liquid helium). An example of this work is the study of radical reactions in single crystals of amino acids exposed to x-rays, work that sometimes leads to activation energies and rate constants for radical reactions.

Medical and biological

Medical and biological applications of EPR also exist. Although radicals are very reactive, so they do not normally occur in high concentrations in biology, special reagents have been developed to attach "spin labels", also called "spin probes", to molecules of interest. Specially-designed nonreactive radical molecules can attach to specific sites in a biological cell, and EPR spectra then give information on the environment of the spin labels. Spin-labeled fatty acids have been extensively used to study dynamic organisation of lipids in biological membranes, lipid-protein interactions and temperature of transition of gel to liquid crystalline phases. Injection of spin-labeled molecules allows for electron resonance imaging of living organisms.

A type of dosimetry system has been designed for reference standards and routine use in medicine, based on EPR signals of radicals from irradiated polycrystalline α-alanine (the alanine deamination radical, the hydrogen abstraction radical, and the (CO⁻(OH))=C(CH₃)NH+2 radical). This method is suitable for measuring gamma and X-rays, electrons, protons, and high-linear energy transfer (LET) radiation of doses in the 1 Gy to 100 kGy range.

EPR can be used to measure microviscosity and micropolarity within drug delivery systems as well as the characterization of colloidal drug carriers.

The study of radiation-induced free radicals in biological substances (for cancer research) poses the additional problem that tissue contains water, and water (due to its electric dipole moment) has a strong absorption band in the microwave region used in EPR spectrometers.

Material characterization

EPR/ESR spectroscopy is used in geology and archaeology as a dating tool. It can be applied to a wide range of materials such as organic shales, carbonates, sulfates, phosphates, silica or other silicates. When applied to shales, the EPR data correlates to the maturity of the kerogen in the shale.

EPR spectroscopy has been used to measure properties of crude oil, such as determination of asphaltene and vanadium content. The free-radical component of the EPR signal is proportional to the amount of asphaltene in the oil regardless of any solvents, or precipitants that may be present in that oil. When the oil is subject to a precipitant such as hexane, heptane, pyridine however, then much of the asphaltene can be subsequently extracted from the oil by gravimetric techniques. The EPR measurement of that extract will then be function of the polarity of the precipitant that was used. Consequently, it is preferable to apply the EPR measurement directly to the crude. In the case that the measurement is made upstream of a separator (oil production), then it may also be necessary determine the oil fraction within the crude (e.g., if a certain crude contains 80% oil and 20% water, then the EPR signature will be 80% of the signature of downstream of the separator).

EPR has been used by archaeologists for the dating of teeth. Radiation damage over long periods of time creates free radicals in tooth enamel, which can then be examined by EPR and, after proper calibration, dated. Similarly, material extracted from the teeth of people during dental procedures can be used to quantify their cumulative exposure to ionizing radiation. People (and other mammals) exposed to radiation from the atomic bombs, from the Chernobyl disaster, and from the Fukushima accident have been examined by this method.

Radiation-sterilized foods have been examined with EPR spectroscopy, aiming to develop methods to determine whether a food sample has been irradiated and to what dose.

Other applications

In the field of quantum computing, pulsed EPR is used to control the state of electron spin qubits in materials such as diamond, silicon and gallium arsenide.

High-field high-frequency measurements

High-field high-frequency EPR measurements are sometimes needed to detect subtle spectroscopic details. However, for many years the use of electromagnets to produce the needed fields above 1.5 T was impossible, due principally to limitations of traditional magnet materials. The first multifunctional millimeter EPR spectrometer with a superconducting solenoid was described in the early 1970s by Prof. Y. S. Lebedev's group (Russian Institute of Chemical Physics, Moscow) in collaboration with L. G. Oranski's group (Ukrainian Physics and Technics Institute, Donetsk), which began working in the Institute of Problems of Chemical Physics, Chernogolovka around 1975. Two decades later, a W-band EPR spectrometer was produced as a small commercial line by the German Bruker Company, initiating the expansion of W-band EPR techniques into medium-sized academic laboratories.

Waveband	L	S	C	X	P	K	Q	U	V	E	W	F	D	—	J	—
${\displaystyle \lambda /\text{mm}}$	300	100	75	30	20	12.5	8.5	6	4.6	4	3.2	2.7	2.1	1.6	1.1	0.83
${\displaystyle \nu /\text{GHz}}$	1	3	4	10	15	24	35	50	65	75	95	111	140	190	285	360
${\displaystyle B_0/\text{T}}$	0.03	0.11	0.14	0.33	0.54	0.86	1.25	1.8	2.3	2.7	3.5	3.9	4.9	6.8	10.2	12.8

Variation in the EPR spectrum of the TEMPO nitroxide radical as the microwave band (energy of excitation) changes. Note the improved resolution as frequency rises (neglecting the influence of g strain).

The EPR waveband is stipulated by the frequency or wavelength of a spectrometer's microwave source (see Table).

EPR experiments often are conducted at X and, less commonly, Q bands, mainly due to the ready availability of the necessary microwave components (which originally were developed for radar applications). A second reason for widespread X and Q band measurements is that electromagnets can reliably generate fields up to about 1 tesla. However, the low spectral resolution over g-factor at these wavebands limits the study of paramagnetic centers with comparatively low anisotropic magnetic parameters. Measurements at ${\displaystyle \nu }$ > 40 GHz, in the millimeter wavelength region, offer the following advantages:

1. EPR spectra are simplified due to the reduction of second-order effects at high fields.
2. Increase in orientation selectivity and sensitivity in the investigation of disordered systems.
3. The informativity and precision of pulse methods, e.g., ENDOR also increase at high magnetic fields.
4. Accessibility of spin systems with larger zero-field splitting due to the larger microwave quantum energy h${\displaystyle \nu }$.
5. The higher spectral resolution over g-factor, which increases with irradiation frequency ${\displaystyle \nu }$ and external magnetic field B₀. This is used to investigate the structure, polarity, and dynamics of radical microenvironments in spin-modified organic and biological systems through the spin label and probe method. The figure shows how spectral resolution improves with increasing frequency.
6. Saturation of paramagnetic centers occurs at a comparatively low microwave polarizing field B₁, due to the exponential dependence of the number of excited spins on the radiation frequency ${\displaystyle \nu }$. This effect can be successfully used to study the relaxation and dynamics of paramagnetic centers as well as of superslow motion in the systems under study.
7. The cross-relaxation of paramagnetic centers decreases dramatically at high magnetic fields, making it easier to obtain more-precise and more-complete information about the system under study.

This was demonstrated experimentally in the study of various biological, polymeric and model systems at D-band EPR.

Hardware components

3D model of a typical X-band CW-EPR spectrometer

Microwave bridge

The microwave bridge contains both the microwave source and the detector. Older spectrometers used a vacuum tube called a klystron to generate microwaves, but modern spectrometers use a Gunn diode. Immediately after the microwave source there is an isolator which serves to attenuate any reflections back to the source which would result in fluctuations in the microwave frequency. The microwave power from the source is then passed through a directional coupler which splits the microwave power into two paths, one directed towards the cavity and the other the reference arm. Along both paths there is a variable attenuator that facilitates the precise control of the flow of microwave power. This in turn allows for accurate control over the intensity of the microwaves subjected to the sample. On the reference arm, after the variable attenuator there is a phase shifter that sets a defined phase relationship between the reference and reflected signal which permits phase sensitive detection.

Most EPR spectrometers are reflection spectrometers, meaning that the detector should only be exposed to microwave radiation coming back from the cavity. This is achieved by the use of a device known as the circulator which directs the microwave radiation (from the branch that is heading towards the cavity) into the cavity. Reflected microwave radiation (after absorption by the sample) is then passed through the circulator towards the detector, ensuring it does not go back to the microwave source. The reference signal and reflected signal are combined and passed to the detector diode which converts the microwave power into an electrical current.

Reference arm

At low energies (less than 1 μW) the diode current is proportional to the microwave power and the detector is referred to as a square-law detector. At higher power levels (greater than 1 mW) the diode current is proportional to the square root of the microwave power and the detector is called a linear detector. In order to obtain optimal sensitivity as well as quantitative information the diode should be operating within the linear region. To ensure the detector is operating at that level the reference arm serves to provide a "bias".

Magnet

In an EPR spectrometer the magnetic assembly includes the magnet with a dedicated power supply as well as a field sensor or regulator such as a Hall probe. EPR spectrometers use one of two types of magnet which is determined by the operating microwave frequency (which determine the range of magnetic field strengths required). The first is an electromagnet which are generally capable of generating field strengths of up to 1.5 T making them suitable for measurements using the Q-band frequency. In order to generate field strengths appropriate for W-band and higher frequency operation superconducting magnets are employed. The magnetic field is homogeneous across the sample volume and has a high stability at static field.

Microwave resonator (cavity)

The microwave resonator is designed to enhance the microwave magnetic field at the sample in order to induce EPR transitions. It is a metal box with a rectangular or cylindrical shape that resonates with microwaves (like an organ pipe with sound waves). At the resonance frequency of the cavity microwaves remain inside the cavity and are not reflected back. Resonance means the cavity stores microwave energy and its ability to do this is given by the quality factor Q, defined by the following equation:

${\displaystyle Q=\frac{2\pi (\text{energy stored})}{(\text{energy dissipated})}}$

The higher the value of Q the higher the sensitivity of the spectrometer. The energy dissipated is the energy lost in one microwave period. Energy may be lost to the side walls of the cavity as microwaves may generate currents which in turn generate heat. A consequence of resonance is the creation of a standing wave inside the cavity. Electromagnetic standing waves have their electric and magnetic field components exactly out of phase. This provides an advantage as the electric field provides non-resonant absorption of the microwaves, which in turn increases the dissipated energy and reduces Q. To achieve the largest signals and hence sensitivity the sample is positioned such that it lies within the magnetic field maximum and the electric field minimum. When the magnetic field strength is such that an absorption event occurs, the value of Q will be reduced due to the extra energy loss. This results in a change of impedance which serves to stop the cavity from being critically coupled. This means microwaves will now be reflected back to the detector (in the microwave bridge) where an EPR signal is detected.

Pulsed electron paramagnetic resonance

Further information: Pulsed electron paramagnetic resonance

The dynamics of electron spins are best studied with pulsed measurements. Microwave pulses typically 10–100 ns long are used to control the spins in the Bloch sphere. The spin–lattice relaxation time can be measured with an inversion recovery experiment.

As with pulsed NMR, the Hahn echo is central to many pulsed EPR experiments. A Hahn echo decay experiment can be used to measure the dephasing time, as shown in the animation below. The size of the echo is recorded for different spacings of the two pulses. This reveals the decoherence, which is not refocused by the ${\displaystyle \pi }$ pulse. In simple cases, an exponential decay is measured, which is described by the ${\displaystyle T_2}$ time.

Pulsed electron paramagnetic resonance could be advanced into electron nuclear double resonance spectroscopy (ENDOR), which utilizes waves in the radio frequencies. Since different nuclei with unpaired electrons respond to different wavelengths, radio frequencies are required at times. Since the results of the ENDOR gives the coupling resonance between the nuclei and the unpaired electron, the relationship between them can be determined.

Brain tumor

From Wikipedia, the free encyclopedia
https://en.wikipedia.org/wiki/Brain_tumor

 

Brain tumor
Other names	Intracranial neoplasm, brain tumour
Brain metastasis in the right cerebral hemisphere from lung cancer, shown on magnetic resonance imaging
Specialty	Neurosurgery, Neuro-oncology
Symptoms	Vary depending on the part of the brain involved, headaches, seizures, problem with vision, vomiting, mental changes
Types	Malignant, benign
Causes	Usually unknown
Risk factors	Neurofibromatosis, exposure to vinyl chloride, Epstein–Barr virus, ionizing radiation
Diagnostic method	Computed tomography, magnetic resonance imaging, tissue biopsy
Treatment	Surgery, radiation therapy, chemotherapy
Medication	Anticonvulsants, dexamethasone, furosemide
Prognosis	Average five-year survival rate 33% (US)
Frequency	1.2 million nervous system cancers (2015)
Deaths	228,800 (worldwide, 2015)

A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors: malignant (cancerous) tumors and benign (non-cancerous) tumors. These can be further classified as primary tumors, which start within the brain, and secondary tumors, which most commonly have spread from tumors located outside the brain, known as brain metastasis tumors. All types of brain tumors may produce symptoms that vary depending on the size of the tumor and the part of the brain that is involved. Where symptoms exist, they may include headaches, seizures, problems with vision, vomiting and mental changes. Other symptoms may include difficulty walking, speaking, with sensations, or unconsciousness.

The cause of most brain tumors is unknown, though up to 4% of brain cancers may be caused by CT scan radiation. Uncommon risk factors include exposure to vinyl chloride, Epstein–Barr virus, ionizing radiation, and inherited syndromes such as neurofibromatosis, tuberous sclerosis, and von Hippel-Lindau Disease. Studies on mobile phone exposure have not shown a clear risk. The most common types of primary tumors in adults are meningiomas (usually benign) and astrocytomas such as glioblastomas. In children, the most common type is a malignant medulloblastoma. Diagnosis is usually by medical examination along with computed tomography (CT) or magnetic resonance imaging (MRI). The result is then often confirmed by a biopsy. Based on the findings, the tumors are divided into different grades of severity.

Treatment may include some combination of surgery, radiation therapy and chemotherapy. If seizures occur, anticonvulsant medication may be needed. Dexamethasone and furosemide are medications that may be used to decrease swelling around the tumor. Some tumors grow gradually, requiring only monitoring and possibly needing no further intervention. Treatments that use a person's immune system are being studied. Outcomes for malignant tumors vary considerably depending on the type of tumor and how far it has spread at diagnosis. Although benign tumors only grow in one area, they may still be life-threatening depending on their size and location. Malignant glioblastomas usually have very poor outcomes, while benign meningiomas usually have good outcomes. The average five-year survival rate for all (malignant) brain cancers in the United States is 33%.

Secondary, or metastatic, brain tumors are about four times as common as primary brain tumors, with about half of metastases coming from lung cancer. Primary brain tumors occur in around 250,000 people a year globally, and make up less than 2% of cancers. In children younger than 15, brain tumors are second only to acute lymphoblastic leukemia as the most common form of cancer. In NSW Australia in 2005, the average lifetime economic cost of a case of brain cancer was AU$1.9 million, the greatest of any type of cancer.

Signs and symptoms

The signs and symptoms of brain tumors are broad. People may experience symptoms regardless of whether the tumor is benign (not cancerous) or cancerous. Primary and secondary brain tumors present with similar symptoms, depending on the location, size, and rate of growth of the tumor. For example, larger tumors in the frontal lobe can cause changes in the ability to think. However, a smaller tumor in an area such as Wernicke's area (small area responsible for language comprehension) can result in a greater loss of function.

Headaches

Headaches as a result of raised intracranial pressure can be an early symptom of brain cancer. However, isolated headache without other symptoms is rare, and other symptoms including visual abnormalities may occur before headaches become common. Certain warning signs for headache exist which make the headache more likely to be associated with brain cancer. These are defined as "abnormal neurological examination, headache worsened by Valsalva maneuver, headache causing awakening from sleep, new headache in the older population, progressively worsening headache, atypical headache features, or patients who do not fulfill the strict definition of migraine". Other associated signs are headaches that are worse in the morning or that subside after vomiting.

Location-specific symptoms

The main areas of the brain and limbic system

The brain is divided into lobes and each lobe or area has its own function. A tumor in any of these lobes may affect the area's performance. The symptoms experienced are often linked to the location of the tumor, but each person may experience something different.

• Frontal lobe: Tumors may contribute to poor reasoning, inappropriate social behavior, personality changes, poor planning, lower inhibition, and decreased production of speech (Broca's area).
• Temporal lobe: Tumors in this lobe may contribute to poor memory, loss of hearing, and difficulty in language comprehension (Wernicke's area is located in this lobe).
• Parietal lobe: Tumors here may result in poor interpretation of languages, difficulty with speaking, writing, drawing, naming, and recognizing, and poor spatial and visual perception.
• Occipital lobe: Damage to this lobe may result in poor vision or loss of vision.
• Cerebellum: Tumors in this area may cause poor balance, muscle movement, and posture.
• Brain stem: Tumors on the brainstem can cause seizures, endocrine problems, respiratory changes, visual changes, headaches and partial paralysis.

Behavior changes

A person's personality may be altered due to the tumor-damaging lobes of the brain. Since the frontal, temporal, and parietal lobes control inhibition, emotions, mood, judgement, reasoning, and behavior, a tumor in those regions can cause inappropriate social behavior, temper tantrums, laughing at things which merit no laughter, and even psychological symptoms such as depression and anxiety. More research is needed into the effectiveness and safety of medication for depression in people with brain tumors.

Personality changes can have damaging effects such as unemployment, unstable relationships, and a lack of control.

Cause

The best-known cause of brain cancers is ionizing radiation. Approximately 4% of brain cancers in the general population are caused by CT-scan radiation. For brain cancers that follow a CT scan at lags of 2 years or more, it has been estimated that 40% are attributable to CT-scan radiation. The relationship between ionizing radiation and brain cancers can be best explained by radiation carcinogenesis, and by traditional models of oncogenesis. The stochastic effects of ionizing radiation demonstrate a dose-response relationship to the probability of occurrence, but no dose-response relationship to severity of disease. The majority of radiation-induced brain cancers are caused by ionizing radiation from medical sources such as CT scans.

Mutations and deletions of tumor suppressor genes, such as P53, are thought to be the cause of some forms of brain tumor. Inherited conditions, such as Von Hippel–Lindau disease, tuberous sclerosis, multiple endocrine neoplasia, and neurofibromatosis type 2 carry a high risk for the development of brain tumors. People with celiac disease have a slightly increased risk of developing brain tumors. Smoking may increase the risk, but evidence of this remains unclear.

Although studies have not shown any link between cell-phone or mobile-phone radiation and the occurrence of brain tumors, the World Health Organization has classified mobile-phone radiation on the IARC scale into Group 2B – possibly carcinogenic. The claim that cell-phone usage may cause brain cancer is likely based on epidemiological studies which observed a slight increase in glioma risk among heavy users of wireless phones. When those studies were conducted, GSM (2G) phones were in use. Modern, third-generation (3G) phones emit, on average, about 1% of the energy emitted by those GSM (2G) phones, and therefore the finding of an association between cell-phone usage and increased risk of brain cancer is not based upon current phone usage.

Pathophysiology

Meninges

The meninges lie between the skull and brain matter. Tumors originating from the meninges are meningiomas.

Human brains are surrounded by a system of connective tissue membranes called meninges that separate the brain from the skull. This three-layered covering is composed of (from the outside in) the dura mater, arachnoid mater, and pia mater. The arachnoid and pia are physically connected and thus often considered as a single layer, the leptomeninges. Between the arachnoid mater and the pia mater is the subarachnoid space which contains cerebrospinal fluid (CSF). This fluid circulates in the narrow spaces between cells and through the cavities in the brain called ventricles, to support and protect the brain tissue. Blood vessels enter the central nervous system through the perivascular space above the pia mater. The cells in the blood vessel walls are joined tightly, forming the blood–brain barrier which protects the brain from toxins that might enter through the blood.

Tumors of the meninges are meningiomas and are often benign. Though not technically a tumor of brain tissue, they are often considered brain tumors since they protrude into the space where the brain is, causing symptoms. Since they are usually slow-growing tumors, meningiomas can be quite large by the time symptoms appear.

Brain matter

The brains of humans and other vertebrates are composed of very soft tissue and have a gelatin-like texture. Living brain tissue has a pink tint in color on the outside (gray matter), and nearly complete white on the inside (white matter), with subtle variations in color. The three largest divisions of the brain are:

• Cerebral cortex
• Brainstem
• Cerebellum

These areas are composed of two broad classes of cells: neurons and glia. These two types are equally numerous in the brain as a whole, although glial cells outnumber neurons roughly 4 to 1 in the cerebral cortex. Glia come in several types, which perform a number of critical functions, including structural support, metabolic support, insulation, and guidance of development. Primary tumors of the glial cells are called gliomas and often are malignant by the time they are diagnosed.

The thalamus and hypothalamus are major divisions of the diencephalon, with the pituitary gland and pineal gland attached at the bottom; tumors of the pituitary and pineal gland are often benign.

The brainstem lies between the large cerebral cortex and the spinal cord. It is divided into the midbrain, pons, and medulla oblongata.

Spinal cord

The spinal cord is considered a part of the central nervous system. It is made up of the same cells as the brain: neurons and glial cells.

Diagnosis

A posterior fossa tumor leading to mass effect and midline shift

Although there is no specific or singular symptom or sign, the presence of a combination of symptoms and the lack of corresponding indications of other causes can be an indicator for investigation towards the possibility of a brain tumor. Brain tumors have similar characteristics and obstacles when it comes to diagnosis and therapy with tumors located elsewhere in the body. However, they create specific issues that follow closely to the properties of the organ they are in.

The diagnosis will often start by taking a medical history noting medical antecedents, and current symptoms. Clinical and laboratory investigations will serve to exclude infections as the cause of the symptoms. Examinations in this stage may include the eyes, otolaryngological (or ENT) and electrophysiological exams. The use of electroencephalography (EEG) often plays a role in the diagnosis of brain tumors.

Brain tumors, when compared to tumors in other areas of the body, pose a challenge for diagnosis. Commonly, radioactive tracers are uptaken in large volumes in tumors due to the high activity of tumor cells, allowing for radioactive imaging of the tumor. However, most of the brain is separated from the blood by the blood–brain barrier (BBB), a membrane that exerts a strict control over what substances are allowed to pass into the brain. Therefore, many tracers that may reach tumors in other areas of the body easily would be unable to reach brain tumors until there was a disruption of the BBB by the tumor. Disruption of the BBB is well imaged via MRI or CT scan, and is therefore regarded as the main diagnostic indicator for malignant gliomas, meningiomas, and brain metastases.

Swelling or obstruction of the passage of cerebrospinal fluid (CSF) from the brain may cause (early) signs of increased intracranial pressure which translates clinically into headaches, vomiting, or an altered state of consciousness, and in children changes to the diameter of the skull and bulging of the fontanelles. More complex symptoms such as endocrine dysfunctions should alarm doctors not to exclude brain tumors.

A bilateral temporal visual field defect (due to compression of the optic chiasm) or dilation of the pupil, and the occurrence of either slowly evolving or the sudden onset of focal neurologic symptoms, such as cognitive and behavioral impairment (including impaired judgment, memory loss, lack of recognition, spatial orientation disorders), personality or emotional changes, hemiparesis, hypoesthesia, aphasia, ataxia, visual field impairment, impaired sense of smell, impaired hearing, facial paralysis, double vision, or more severe symptoms such as tremors, paralysis on one side of the body hemiplegia, or (epileptic) seizures in a patient with a negative history for epilepsy, should raise the possibility of a brain tumor.

Imaging

CT scan of a brain tumor, with its diameters marked as an X. There is hypoattenuating (dark) peritumoral edema in the surrounding white matter, with a "finger-like" spread.

Medical imaging plays a central role in the diagnosis of brain tumors. Early imaging methods – invasive and sometimes dangerous – such as pneumoencephalography and cerebral angiography have been abandoned in favor of non-invasive, high-resolution techniques, especially magnetic resonance imaging (MRI) and computed tomography (CT) scans, though MRI is typically the reference standard used. Neoplasms will often show as differently colored masses (also referred to as processes) in CT or MRI results.

• Benign brain tumors often show up as hypodense (darker than brain tissue) mass lesions on CT scans. On MRI, they appear either hypodense or isointense (same intensity as brain tissue) on T1-weighted scans, or hyperintense (brighter than brain tissue) on T2-weighted MRI, although the appearance is variable.
• Contrast agent uptake, sometimes in characteristic patterns, can be demonstrated on either CT or MRI scans in most malignant primary and metastatic brain tumors.
• Pressure areas where the brain tissue has been compressed by a tumor also appear hyperintense on T2-weighted scans and might indicate the presence of a diffuse neoplasm due to an unclear outline. Swelling around the tumor known as peritumoral edema can also show a similar result. This is because these tumors disrupt the normal functioning of the BBB and lead to an increase in its permeability.

More recently, advancements have been made to increase the utility of MRI in providing physiological data that can help to inform diagnosis and prognosis. MRI itself is sufficient in identifying the brain tumor's location and morphology, but other types of MRI may be used on top of that, such as MRA, MRS, pMRI, fMRI, and DWI. These imaging techniques help doctors and surgeons to diagnose the type of tumor, plan for surgery, and to assess treatment and radiation/chemotherapy. Treatment with radiation and chemotherapy can lead to treatment induced changes in the brain, visible on conventional imaging and which can be difficult to differentiate from tumor recurrence.

Different Types of MRI Scans

Magnetic Resonance Angiography (MRA) – looks at the blood vessels in the brain. In the diagnosis of brain tumor, MRAs are typically carried out before surgery to help surgeons get a better understanding of the tumor vasculature. For example, a study was done where surgeons were able to separate benign brain tumors from malignant ones by analyzing the shapes of the blood vessels that were extracted from MRA. Although not required, some MRA may inject contrast agent, gadolinium, into the patient to get an enhanced image

Magnetic Resonance Spectroscopy (MRS) – measures the metabolic changes or chemical changes inside the tumor. The most common MRS is proton spectroscopy with its frequency measured in parts per million (ppm). Gliomas or malignant brain tumors have different spectra from normal brain tissue in that they have greater choline levels and lower N-acetyl aspartate (NAA) signals. Using MRS in brain tumor diagnosis can help doctors identify the type of tumor and its aggressiveness. For example, benign brain tumors or meningioma have increased alanine levels. It can also help to distinguish brain tumors from scar tissues or dead tissues caused by previous radiation treatment, which does not have increased choline levels that brain tumors have, and from tumor-mimicking lesions such as abscesses or infarcts.

Perfusion Magnetic Resonance Imaging (pMRI) – assess the blood volume and blood flow of different parts of the brain and brain tumors. pMRI requires the injection of contrast agent, usually gadopentetate dimeglumine (Gd-DTPA) into the veins in order to enhance the contrast. pMRI provides a cerebral blood volume map that shows the tumor vascularity and angiogenesis. Brain tumors would require a larger blood supply and thus, would show a high cerebral blood volume on the pMRI map. The vascular morphology and degree of angiogenesis from pMRI help to determine the grade and malignancy of brain tumors. For brain tumor diagnosis, pMRI is useful in determining the best site to perform biopsy and to help reduce sampling error. pMRI is also valuable for after treatment to determine if the abnormal area is a remaining tumor or a scar tissue. For patients that are undergoing anti-angiogenesis cancer therapy, pMRI can give the doctors a better sense of efficacy of the treatment by monitoring tumor cerebral blood volume.

Functional MRI (fMRI) – measures blood flow changes in active parts of the brain while the patient is performing tasks and provides specific locations of the brain that are responsible for certain functions. Before performing a brain tumor surgery on patients, neurosurgeons would use fMRI to avoid damage to structures of the brain that correspond with important brain functions while resecting the tumor at the same time. Preoperative fMRI is important because it is often difficult to distinguish the anatomy near the tumor as it distorts its surrounding regions. Neurosurgeons would use fMRI to plan whether to perform a resection where tumor is surgically removed as much as possible, a biopsy where they take a surgical sampling amount to provide a diagnosis, or to not undergo surgery at all. For example, a neurosurgeon may be opposed to resecting a tumor near the motor cortex as that would affect the patient's movements. Without preoperative fMRI, the neurosurgeon would have to perform an awake-craniotomy where the patient would have to interact during open surgery to see if tumor removal would affect important brain functions.

Diffusion Weighted Imaging (DWI) – a form of MRI that measures random Brownian motion of water molecules along a magnetic field gradient. For brain tumor diagnosis, measurement of apparent diffusion coefficient (ADC) in brain tumors allow doctors to categorize tumor type. Most brain tumors have higher ADC than normal brain tissues and doctors can match the observed ADC of the patient's brain tumor with a list of accepted ADC to identify tumor type. DWI is also useful for treatment and therapy purposes where changes in diffusion can be analyzed in response to drug, radiation, or gene therapy. Successful response results in apoptosis and increase in diffusion while failed treatment results in unchanged diffusion values.

Other Types of Imaging Techniques

Computed Tomography (CT) Scan – uses x-rays to take pictures from different angles and computer processing to combine the pictures into a 3D image. A CT scan usually serves as an alternative to MRI in cases where the patient cannot have an MRI due to claustrophobia or pacemaker. Compared to MRI, a CT scan shows a more detailed image of the bone structures near the tumor and can be used to measure the tumor's size. Like an MRI, a contrast dye may also be injected into the veins or ingested by mouth before a CT scan to better outline any tumors that may be present. CT scans use contrast materials that are iodine-based and barium sulfate compounds. The downside of using CT scans as opposed to MRI is that some brain tumors do not show up well on CT scans because some intra-axial masses are faint and resemble normal brain tissue. In some scenarios, brain tumors in CT scans may be mistaken for infarction, infection, and demyelination. To suspect that an intra-axial mass is a brain tumor instead of other possibilities, there must be unexplained calcifications in the brain, preservation of the cortex, and disproportionate mass effect.

CT Angiography (CTA) – provides information about the blood vessels in the brain using X-rays. A contrast agent is always required to be injected into the patient in the CT scanner. CTA serves as an alternative to MRA.

Positron Emission Tomography (PET) Scan – uses radioactive substances, with the most common one being a sugar known as FDG, while more specific tracers for glioma are emerging. This injected substance is taken up by cells that are actively dividing. Tumor cells are more active in dividing so they would absorb more of the radioactive substance. After injection, a scanner would be used to create an image of the radioactive areas in the brain. PET scans are used more often for high-grade tumors than for low-grade tumors. It is useful after treatment to help doctors determine if the abnormal area on an MRI image is a remaining tumor or a scar tissue. Scar tissues will not show up on PET scans while tumors would.

However, these techniques cannot alone diagnose high- versus low-grade gliomas, and thus the definitive diagnosis of brain tumor should only be confirmed by histological examination of tumor tissue samples obtained either by means of brain biopsy or open surgery. The histological examination is essential for determining the appropriate treatment and the correct prognosis. This examination, performed by a pathologist, typically has three stages: interoperative examination of fresh tissue, preliminary microscopic examination of prepared tissues, and follow-up examination of prepared tissues after immunohistochemical staining or genetic analysis.

Pathology

Micrograph of an oligodendroglioma, a type of brain cancer. Brain biopsy. H&E stain.

Tumors have characteristics that allow the determination of malignancy and how they will evolve, and determining these characteristics will allow the medical team to determine the management plan.

Anaplasia or dedifferentiation: loss of differentiation of cells and of their orientation to one another and blood vessels, a characteristic of anaplastic tumor tissue. Anaplastic cells have lost total control of their normal functions and many have deteriorated cell structures. Anaplastic cells often have abnormally high nuclear-to-cytoplasmic ratios, and many are multinucleated. Additionally, the nucleus of anaplastic cells is usually unnaturally shaped or oversized. Cells can become anaplastic in two ways: neoplastic tumor cells can dedifferentiate to become anaplasias (the dedifferentiation causes the cells to lose all of their normal structure/function), or cancer stem cells can increase their capacity to multiply (i.e., uncontrollable growth due to failure of differentiation).

Atypia: an indication of abnormality of a cell (which may be indicative of malignancy). Significance of the abnormality is highly dependent on context.

Neoplasia: the (uncontrolled) division of cells. As such, neoplasia is not problematic but its consequences are: the uncontrolled division of cells means that the mass of a neoplasm increases in size, and in a confined space such as the intracranial cavity this quickly becomes problematic because the mass invades the space of the brain pushing it aside, leading to compression of the brain tissue and increased intracranial pressure and destruction of brain parenchyma. Increased intracranial pressure (ICP) may be attributable to the direct mass effect of the tumor, increased blood volume, or increased cerebrospinal fluid (CSF) volume, which may, in turn, have secondary symptoms.

Necrosis: the (premature) death of cells, caused by external factors such as infection, toxin or trauma. Necrotic cells send the wrong chemical signals which prevent phagocytes from disposing of the dead cells, leading to a buildup of dead tissue, cell debris and toxins at or near the site of the necrotic cells

Arterial and venous hypoxia, or the deprivation of adequate oxygen supply to certain areas of the brain, occurs when a tumor makes use of nearby blood vessels for its supply of blood and the neoplasm enters into competition for nutrients with the surrounding brain tissue. More generally a neoplasm may cause release of metabolic end products (e.g., free radicals, altered electrolytes, neurotransmitters), and release and recruitment of cellular mediators (e.g., cytokines) that disrupt normal parenchymal function.

Classification

Tumors can be benign or malignant, can occur in different parts of the brain, and may be classified as primary or secondary. A primary tumor is one that has started in the brain, as opposed to a metastatic tumor, which is one that has spread to the brain from another area of the body. The incidence of metastatic tumors is approximately four times greater than primary tumors. Tumors may or may not be symptomatic: some tumors are discovered because the patient has symptoms, others show up incidentally on an imaging scan, or at an autopsy.

Grading of the tumors of the central nervous system commonly occurs on a 4-point scale (I-IV) created by the World Health Organization in 1993. Grade I tumors are the least severe and commonly associated with long-term survival, with severity and prognosis worsening as the grade increases. Low-grade tumors are often benign, while higher grades are aggressively malignant and/or metastatic. Other grading scales do exist, many based upon the same criteria as the WHO scale and graded from I-IV.

Primary

Meningioma of the middle third of the sagittal sinus with large hyperostosis

The most common primary brain tumors are:

• Gliomas (50.4%)
• Meningiomas (20.8%)
• Pituitary adenomas (15%)
• Nerve sheath tumors (10%)

These common tumors can also be organized according to tissue of origin as shown below:

Tissue of origin	Children	Adults
Astrocytes	Pilocytic Astrocytoma (PCA)	Glioblastoma
Oligodendrocytes		Oligodendroglioma
Ependyma	Ependymoma
Neurons	Medulloblastoma
Meninges		Meningioma

Secondary

Secondary tumors of the brain are metastatic and have invaded the brain from cancers originating in other organs. This means that a cancerous neoplasm has developed in another organ elsewhere in the body and that cancer cells have leaked from that primary tumor and then entered the lymphatic system and blood vessels. They then circulate through the bloodstream, and are deposited in the brain. There, these cells continue growing and dividing, becoming another invasive neoplasm of primary cancer's tissue. Secondary tumors of the brain are very common in the terminal phases of patients with an incurable metastasized cancer; the most common types of cancers that bring about secondary tumors of the brain are lung cancer, breast cancer, malignant melanoma, kidney cancer, and colon cancer (in decreasing order of frequency).

Secondary brain tumors are more common than primary ones; in the United States, there are about 170,000 new cases every year. Secondary brain tumors are the most common cause of tumors in the intracranial cavity. The skull bone structure can also be subject to a neoplasm that by its very nature reduces the volume of the intracranial cavity, and can damage the brain.

By behavior

Brain tumors or intracranial neoplasms can be cancerous (malignant) or non-cancerous (benign). However, the definitions of malignant or benign neoplasms differ from those commonly used in other types of cancerous or non-cancerous neoplasms in the body. In cancers elsewhere in the body, three malignant properties differentiate benign tumors from malignant forms of cancer: benign tumors are self-limited and do not invade or metastasize. Characteristics of malignant tumors include:

• uncontrolled mitosis (growth by division beyond the normal limits)
• anaplasia: the cells in the neoplasm have an obviously different form (in size and shape). Anaplastic cells display marked pleomorphism. The cell nuclei are characteristically extremely hyperchromatic (darkly stained) and enlarged; the nucleus might have the same size as the cytoplasm of the cell (nuclear-cytoplasmic ratio may approach 1:1, instead of the normal 1:4 or 1:6 ratio). Giant cells – considerably larger than their neighbors – may form and possess either one enormous nucleus or several nuclei (syncytia). Anaplastic nuclei are variable and bizarre in size and shape.
• invasion or infiltration (medical literature uses these terms as synonymous equivalents. However, for clarity, the articles that follow adhere to a convention that they mean slightly different things; this convention is not followed outside these articles):
  • Invasion or invasiveness is the spatial expansion of the tumor through uncontrolled mitosis, in the sense that the neoplasm invades the space occupied by adjacent tissue, thereby pushing the other tissue aside and eventually compressing the tissue. Often these tumors are associated with clearly outlined tumors in imaging.
  • Infiltration is the behavior of the tumor either to grow (microscopic) tentacles that push into the surrounding tissue (often making the outline of the tumor undefined or diffuse) or to have tumor cells "seeded" into the tissue beyond the circumference of the tumorous mass; this does not mean that an infiltrative tumor does not take up space or does not compress the surrounding tissue as it grows, but an infiltrating neoplasm makes it difficult to say where the tumor ends and the healthy tissue starts.
• metastasis (spread to other locations in the body via lymph or blood).

Of the above malignant characteristics, some elements do not apply to primary neoplasms of the brain:

• Primary brain tumors rarely metastasize to other organs; some forms of primary brain tumors can metastasize but will not spread outside the intracranial cavity or the central spinal canal. Due to the BBB, cancerous cells of a primary neoplasm cannot enter the bloodstream and get carried to another location in the body. (Occasional isolated case reports suggest spread of certain brain tumors outside the central nervous system, e.g. bone metastasis of glioblastoma.)
• Primary brain tumors generally are invasive (i.e. they will expand spatially and intrude into the space occupied by other brain tissue and compress those brain tissues); however, some of the more malignant primary brain tumors will infiltrate the surrounding tissue.

By genetics

In 2016, the WHO restructured their classifications of some categories of gliomas to include distinct genetic mutations that have been useful in differentiating tumor types, prognoses, and treatment responses. Genetic mutations are typically detected via immunohistochemistry, a technique that visualizes the presence or absence of a targeted protein via staining.

• Mutations in IDH1 and IDH2 genes are commonly found in low-grade gliomas
• Loss of both IDH genes combined with loss of chromosome arms 1p and 19q indicates the tumor is an oligodendroglioma
• Loss of TP53 and ATRX characterizes astrocytomas
• Genes EGFR, TERT, and PTEN, are commonly altered in gliomas and are useful in differentiating tumor grade and biology

Specific types

Main article: WHO classification of the tumors of the central nervous system

Anaplastic astrocytoma, Anaplastic oligodendroglioma, Astrocytoma, Central neurocytoma, Choroid plexus carcinoma, Choroid plexus papilloma, Choroid plexus tumor, Colloid cyst, Dysembryoplastic neuroepithelial tumour, Ependymal tumor, Fibrillary astrocytoma, Giant-cell glioblastoma, Glioblastoma, Gliomatosis cerebri, Gliosarcoma, Hemangiopericytoma, Medulloblastoma, Medulloepithelioma, Meningeal carcinomatosis, Neuroblastoma, Neurocytoma, Oligoastrocytoma, Oligodendroglioma, Optic nerve sheath meningioma, Pediatric ependymoma, Pilocytic astrocytoma, Pinealoblastoma, Pineocytoma, Pleomorphic anaplastic neuroblastoma, Pleomorphic xanthoastrocytoma, Primary central nervous system lymphoma, Sphenoid wing meningioma, Subependymal giant cell astrocytoma, Subependymoma, Trilateral retinoblastoma.

Treatment

A medical team generally assesses the treatment options and presents them to the person affected and their family. Various types of treatment are available depending on tumor type and location, and may be combined to produce the best chances of survival:

• Surgery: complete or partial resection of the tumor with the objective of removing as many tumor cells as possible.
• Radiotherapy: the most commonly used treatment for brain tumors; the tumor is irradiated with beta, x rays or gamma rays.
• Chemotherapy: a treatment option for cancer, however, it is not always used to treat brain tumors as the blood–brain barrier can prevent some drugs from reaching the cancerous cells.
• A variety of experimental therapies are available through clinical trials.

Survival rates in primary brain tumors depend on the type of tumor, age, functional status of the patient, the extent of surgical removal and other factors specific to each case.

Standard care for anaplastic oligodendrogliomas and anaplastic oligoastrocytomas is surgery followed by radiotherapy. One study found a survival benefit for the addition of chemotherapy to radiotherapy after surgery, compared with radiotherapy alone.

Surgery

The primary and most desired course of action described in medical literature is surgical removal (resection) via craniotomy. Minimally invasive techniques are becoming the dominant trend in neurosurgical oncology. The main objective of surgery is to remove as many tumor cells as possible, with complete removal being the best outcome and cytoreduction ("debulking") of the tumor otherwise. A Gross Total Resection (GTR) occurs when all visible signs of the tumor are removed, and subsequent scans show no apparent tumor. In some cases access to the tumor is impossible and impedes or prohibits surgery.

Many meningiomas, with the exception of some tumors located at the skull base, can be successfully removed surgically. Most pituitary adenomas can be removed surgically, often using a minimally invasive approach through the nasal cavity and skull base (trans-nasal, trans-sphenoidal approach). Large pituitary adenomas require a craniotomy (opening of the skull) for their removal. Radiotherapy, including stereotactic approaches, is reserved for inoperable cases.

Several current research studies aim to improve the surgical removal of brain tumors by labeling tumor cells with 5-aminolevulinic acid that causes them to fluoresce. Postoperative radiotherapy and chemotherapy are integral parts of the therapeutic standard for malignant tumors.

Multiple metastatic tumors are generally treated with radiotherapy and chemotherapy rather than surgery and the prognosis in such cases is determined by the primary tumor, and is generally poor.

Radiation therapy

The goal of radiation therapy is to kill tumor cells while leaving normal brain tissue unharmed. In standard external beam radiation therapy, multiple treatments of standard-dose "fractions" of radiation are applied to the brain. This process is repeated for a total of 10 to 30 treatments, depending on the type of tumor. This additional treatment provides some patients with improved outcomes and longer survival rates.

Radiosurgery is a treatment method that uses computerized calculations to focus radiation at the site of the tumor while minimizing the radiation dose to the surrounding brain. Radiosurgery may be an adjunct to other treatments, or it may represent the primary treatment technique for some tumors. Forms used include stereotactic radiosurgery, such as Gamma knife, Cyberknife or Novalis Tx radiosurgery.

Radiotherapy is the most common treatment for secondary brain tumors. The amount of radiotherapy depends on the size of the area of the brain affected by cancer. Conventional external beam "whole-brain radiotherapy treatment" (WBRT) or "whole-brain irradiation" may be suggested if there is a risk that other secondary tumors will develop in the future. Stereotactic radiotherapy is usually recommended in cases involving fewer than three small secondary brain tumors. Radiotherapy may be used following, or in some cases in place of, resection of the tumor. Forms of radiotherapy used for brain cancer include external beam radiation therapy, the most common, and brachytherapy and proton therapy, the last especially used for children.

People who receive stereotactic radiosurgery (SRS) and whole-brain radiation therapy (WBRT) for the treatment of metastatic brain tumors have more than twice the risk of developing learning and memory problems than those treated with SRS alone. Results of a 2021 systematic review found that when using SRS as the initial treatment, survival or death related to brain metastasis was not greater than alone versus SRS with WBRT.

Postoperative conventional daily radiotherapy improves survival for adults with good functional well-being and high grade glioma compared to no postoperative radiotherapy. Hypofractionated radiation therapy has similar efficacy for survival as compared to conventional radiotherapy, particularly for individuals aged 60 and older with glioblastoma.

Chemotherapy

Patients undergoing chemotherapy are administered drugs designed to kill tumor cells. Although chemotherapy may improve overall survival in patients with the most malignant primary brain tumors, it does so in only about 20 percent of patients. Chemotherapy is often used in young children instead of radiation, as radiation may have negative effects on the developing brain. The decision to prescribe this treatment is based on a patient's overall health, type of tumor, and extent of cancer. The toxicity and many side effects of the drugs, and the uncertain outcome of chemotherapy in brain tumors puts this treatment further down the line of treatment options with surgery and radiation therapy preferred.

UCLA Neuro-Oncology publishes real-time survival data for patients with a diagnosis of glioblastoma. They are the only institution in the United States that displays how brain tumor patients are performing on current therapies. They also show a listing of chemotherapy agents used to treat high-grade glioma tumors.

Genetic mutations have significant effects on the effectiveness of chemotherapy. Gliomas with IDH1 or IDH2 mutations respond better to chemotherapy than those without the mutation. Loss of chromosome arms 1p and 19q also indicate better response to chemoradiation.

Other

A shunt may be used to relieve symptoms caused by intracranial pressure, by reducing the build-up of fluid (hydrocephalus) caused by the blockage of the free flow of cerebrospinal fluid.

Prognosis

The prognosis of brain cancer depends on the type of cancer diagnosed. Medulloblastoma has a good prognosis with chemotherapy, radiotherapy, and surgical resection while glioblastoma has a median survival of only 15 months even with aggressive chemoradiotherapy and surgery. Brainstem gliomas have the poorest prognosis of any form of brain cancer, with most patients dying within one year, even with therapy that typically consists of radiation to the tumor along with corticosteroids. However, one type, focal brainstem gliomas in children, seems open to exceptional prognosis and long-term survival has frequently been reported.

Prognosis is also affected by presentation of genetic mutations. Certain mutations provide better prognosis than others. IDH1 and IDH2 mutations in gliomas, as well as deletion of chromosome arms 1p and 19q, generally indicate better prognosis. TP53, ATRX, EGFR, PTEN, and TERT mutations are also useful in determining prognosis.

Glioblastoma

Main article: Glioblastoma

Glioblastoma is the most aggressive (grade 4) and most common form of a malignant primary brain tumor. Even when aggressive multimodality therapy consisting of radiotherapy, chemotherapy, and surgical excision is used, median survival is only 15–18 months. Standard therapy for glioblastoma consists of maximal surgical resection of the tumor, followed by radiotherapy between two and four weeks after the surgical procedure to remove the cancer, then by chemotherapy, such as temozolomide. Most patients with glioblastoma take a corticosteroid, typically dexamethasone, during their illness to relieve symptoms. Experimental treatments include targeted therapy, gamma knife radiosurgery, boron neutron capture therapy, gene therapy, and chemowafer implants.

Oligodendrogliomas

Main article: Oligodendroglioma

Oligodendrogliomas are incurable but slowly progressive malignant brain tumors. They can be treated with surgical resection, chemotherapy, radiotherapy or a combination. For some suspected low-grade (grade II) tumors, only a course of watchful waiting and symptomatic therapy is opted for. These tumors show co-deletions of the p and q arms of chromosome 1 and chromosome 19 respectively (1p19q co-deletion) and have been found to be especially chemosensitive with one report claiming them to be one of the most chemosensitive tumors. A median survival of up to 16.7 years has been reported for grade II oligodendrogliomas.

Acoustic neuroma

Acoustic neuromas are non-cancerous tumors. They can be treated with surgery, radiation therapy, or observation. Early intervention with surgery or radiation is recommended to prevent progressive hearing loss.

Epidemiology

Figures for incidences of cancers of the brain show a significant difference between more- and less-developed countries (the less-developed countries have lower incidences of tumors of the brain). This could be explained by undiagnosed tumor-related deaths (patients in extremely poor situations do not get diagnosed, simply because they do not have access to the modern diagnostic facilities required to diagnose a brain tumor) and by deaths caused by other poverty-related causes that preempt a patient's life before tumors develop or tumors become life-threatening. Nevertheless, statistics suggest that certain forms of primary brain tumors are more common among certain populations.

The incidence of low-grade astrocytoma has not been shown to vary significantly with nationality. However, studies examining the incidence of malignant central nervous system (CNS) tumors have shown some variation with national origin. Since some high-grade lesions arise from low-grade tumors, these trends are worth mentioning. Specifically, the incidence of CNS tumors in the United States, Israel, and the Nordic countries is relatively high, while Japan and Asian countries have a lower incidence. These differences probably reflect some biological differences as well as differences in pathologic diagnosis and reporting. Worldwide data on incidence of cancer can be found at the WHO (World Health Organization) and is handled by the IARC (International Agency for Research on Cancer) located in France.

United States

In the United States in 2015, approximately 166,039 people were living with brain or other central nervous system tumors. Over 2018, it was projected that there would be 23,880 new cases of brain tumors and 16,830 deaths in 2018 as a result, accounting for 1.4 percent of all cancers and 2.8 percent of all cancer deaths. Median age of diagnosis was 58 years old, while median age of death was 65. Diagnosis was slightly more common in males, at approximately 7.5 cases per 100 000 people, while females saw 2 fewer at 5.4. Deaths as a result of brain cancer were 5.3 per 100 000 for males, and 3.6 per 100 000 for females, making brain cancer the 10th leading cause of cancer death in the United States. Overall lifetime risk of developing brain cancer is approximated at 0.6 percent for men and women.

UK

Brain, other CNS or intracranial tumors are the ninth most common cancer in the UK (around 10,600 people were diagnosed in 2013), and it is the eighth most common cause of cancer death (around 5,200 people died in 2012).^[102] White British patients with brain tumour are 30% more likely to die within a year of diagnosis than patients from other ethnicities. The reason for this is unknown.^[103]

Children

In the United States more than 28,000 people under 20 are estimated to have a brain tumor. About 3,720 new cases of brain tumors are expected to be diagnosed in those under 15 in 2019. Higher rates were reported in 1985–1994 than in 1975–1983. There is some debate as to the reasons; one theory is that the trend is the result of improved diagnosis and reporting, since the jump occurred at the same time that MRIs became available widely, and there was no coincident jump in mortality. Central nervous system tumors make up 20–25 percent of cancers in children.

The average survival rate for all primary brain cancers in children is 74%. Brain cancers are the most common cancer in children under 19, are result in more death in this group than leukemia. Younger people do less well.

The most common brain tumor types in children (0–14) are: pilocytic astrocytoma, malignant glioma, medulloblastoma, neuronal and mixed neuronal-glial tumors, and ependymoma.

In children under 2, about 70% of brain tumors are medulloblastomas, ependymomas, and low-grade gliomas. Less commonly, and seen usually in infants, are teratomas and atypical teratoid rhabdoid tumors. Germ cell tumors, including teratomas, make up just 3% of pediatric primary brain tumors, but the worldwide incidence varies significantly.

In the UK, 429 children aged 14 and under are diagnosed with a brain tumour on average each year, and 563 children and young people under the age of 19 are diagnosed.

Research

Immunotherapy

Cancer immunotherapy is being actively studied. For malignant gliomas no therapy has been shown to improve life expectancy as of 2015.

Vesicular stomatitis virus

See also: Oncolytic virus

In 2000, researchers used the vesicular stomatitis virus (VSV) to infect and kill cancer cells without affecting healthy cells.

Retroviral replicating vectors

A brainstem glioma in four-year-old. MRI, sagittal, without contrast

Led by Prof. Nori Kasahara, researchers from USC, who are now at UCLA, reported in 2001 the first successful example of applying the use of retroviral replicating vectors towards transducing cell lines derived from solid tumors. Building on this initial work, the researchers applied the technology to in vivo models of cancer and in 2005 reported a long-term survival benefit in an experimental brain tumor animal model. Subsequently, in preparation for human clinical trials, this technology was further developed by Tocagen (a pharmaceutical company primarily focused on brain cancer treatments) as a combination treatment (Toca 511 & Toca FC). This has been under investigation since 2010 in a Phase I/II clinical trial for the potential treatment of recurrent high-grade glioma including glioblastoma and anaplastic astrocytoma. No results have yet been published.

Non-invasive detection

Efforts to detect and monitor development and treatment response of brain tumors by liquid biopsy from blood, cerebrospinal fluid or urine, are in the early stages of development.